Identification

Name
Terazosin
Accession Number
DB01162  (APRD00667)
Type
Small Molecule
Groups
Approved
Description

Terazosin is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Structure
Thumb
Synonyms
  • 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine
  • Terazosina
  • Terazosine
  • Térazosine
  • Terazosinum
External IDs
Abbott 45975
Product Ingredients
IngredientUNIICASInChI Key
Terazosin hydrochloride8QOP8Z995563074-08-8IWSWDOUXSCRCKW-UHFFFAOYSA-N
Terazosin hydrochloride hydrateD32S14F08270024-40-7MWYNOTLRCUQCKD-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-terazosinTablet1 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet10 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet2 mgOralDominion Pharmacal2001-10-31Not applicableCanada
Dom-terazosinTablet5 mgOralDominion Pharmacal2001-10-31Not applicableCanada
HytrinTablet5 mgOralBgp Pharma Ulc1989-12-312017-05-16Canada
HytrinTablet2 mgOralBgp Pharma Ulc1989-12-312016-02-19Canada
HytrinTablet1 mgOralBgp Pharma Ulc1989-12-312016-02-19Canada
HytrinTablet10 mgOralBgp Pharma Ulc1992-12-312016-02-19Canada
Mylan-terazosinTablet5 mgOralMylan Pharmaceuticals2012-11-092016-06-28Canada
Mylan-terazosinTablet1 mgOralMylan Pharmaceuticals2012-11-092016-06-28Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-terazosinTablet10 mgOralApotex Corporation1997-09-26Not applicableCanada
Apo-terazosinTablet2 mgOralApotex Corporation1997-09-26Not applicableCanada
Apo-terazosinTablet5 mgOralApotex Corporation1997-09-26Not applicableCanada
Apo-terazosinTablet1 mgOralApotex Corporation1997-09-26Not applicableCanada
TarazosinCapsule5 mg/1OralMylan Institutional2000-04-01Not applicableUs
TarazosinCapsule1 mg/1OralMylan Institutional2000-04-01Not applicableUs51079 0936 20 nlmimage10 57352bf9
TarazosinCapsule2 mg/1OralMylan Institutional2000-04-01Not applicableUs51079 0937 20 nlmimage10 1e350f18
TerazosinCapsule10 mg/1Oralbryant ranch prepack2004-12-21Not applicableUs59746 0386 06 nlmimage10 a40ed216
TerazosinCapsule2 mg/1OralApotex Corporation2001-04-12Not applicableUs
TerazosinCapsule5 mg/1OralA S Medication Solutions2004-12-202017-06-20Us
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Terazosin HydrochlorideCapsule5 mg/1OralRemedy Repack2017-11-06Not applicableUs
International/Other Brands
Blavin (Baliarda (Argentina)) / Flumarc (Raffo (Argentina)) / Fosfomic (Finadiet (Argentina)) / Heitrin (Abbott (Germany; discontinued)) / Hytrinex (Amdipharm (Sweden)) / Itrin (Keryos (Italy)) / Urodie (Keryos (Italy)) / Vicard (Amdipharm (Austria)) / Zayasel
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgTerazosin (1 mg) + Terazosin (2 mg) + Terazosin (5 mg)Kit; TabletOralAbbott1996-12-312006-10-17Canada
Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgTerazosin (1 mg) + Terazosin (2 mg) + Terazosin (5 mg)Kit; TabletOralAbbott1996-12-312006-10-17Canada
Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgTerazosin (1 mg) + Terazosin (2 mg) + Terazosin (5 mg)Kit; TabletOralAbbott1996-12-312006-10-17Canada
Categories
UNII
8L5014XET7
CAS number
63590-64-7
Weight
Average: 387.4329
Monoisotopic: 387.190654313
Chemical Formula
C19H25N5O4
InChI Key
VCKUSRYTPJJLNI-UHFFFAOYSA-N
InChI
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
IUPAC Name
6,7-dimethoxy-2-[4-(oxolane-2-carbonyl)piperazin-1-yl]quinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1CCCO1

Pharmacology

Indication

For the treatment of symptomatic BPH and mild to moderate hypertension.

Structured Indications
Pharmacodynamics

Terazosin, classified as a quinazoline, is similar to doxazosin and prazosin. As an α-adrenergic blocking agent, terazosin is used to treat hypertension and BPH. Terazosin produces vasodilation and reduces peripheral resistance but in general has only a slight effect on cardiac output. The antihypertensive effect with chronic dosing is not usually accompanied by reflex tachycardia.

Mechanism of action

In general, α1-adrenergic receptors mediate contraction and hypertrophic growth of smooth muscle cells. α1-Receptors are 7-transmembrane domain receptors coupled to G proteins, Gq/11. Three α1-receptor subtypes, which share approximately 75% homology in their transmembrane domains, have been identified: α1A (chromosome 8), α1B (chromosome 5), and α1D (chromosome 20). Terazosin is the first α1-receptor antagonist to demonstrate selectivity for the α1A-receptor. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction. Terozosin produces its pharmacological effects by inhibiting α1A-receptor activation. Inhibition of these receptors in the vasculature and prostate results in muscle relaxation, decreased blood pressure and improved urinary outflow in symptomatic benign prostatic hyperplasia.

TargetActionsOrganism
AAlpha-1A adrenergic receptor
antagonist
Human
AAlpha-1B adrenergic receptor
antagonist
Human
AAlpha-1D adrenergic receptor
antagonist
Human
UPotassium voltage-gated channel subfamily H member 2
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 6
inhibitor
Human
UPotassium voltage-gated channel subfamily H member 7
inhibitor
Human
Absorption

Essentially completely absorbed in man (90% bioavailability).

Volume of distribution
Not Available
Protein binding

90-94%

Metabolism

Hepatic. One of the four metabolites identified (piperazine derivative of terazosin) has antihypertensive activity.

Route of elimination

Approximately 10% of an orally administered dose is excreted as parent drug in the urine and approximately 20% is excreted in the feces.

Half life

12 hours

Clearance
Not Available
Toxicity

LD50=259.3mg/kg (IV in mice)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcebutololAcebutolol may increase the orthostatic hypotensive activities of Terazosin.Approved
AdrafinilTerazosin may decrease the vasoconstricting activities of Adrafinil.Withdrawn
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Terazosin.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Terazosin.Approved
AlfuzosinAlfuzosin may increase the antihypertensive activities of Terazosin.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren.Approved, Investigational
AlprenololAlprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Withdrawn
AmibegronTerazosin may decrease the vasoconstricting activities of Amibegron.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Terazosin.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Terazosin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Terazosin.Approved, Investigational
AmitrazTerazosin may decrease the vasoconstricting activities of Amitraz.Vet Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Terazosin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Terazosin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Terazosin.Approved, Investigational
AmrinoneTerazosin may increase the hypotensive activities of Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Terazosin is combined with Amyl Nitrite.Approved
AnisodamineTerazosin may decrease the vasoconstricting activities of Anisodamine.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Terazosin.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Terazosin.Approved
ArbutamineTerazosin may decrease the vasoconstricting activities of Arbutamine.Approved
ArformoterolTerazosin may decrease the vasoconstricting activities of Arformoterol.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Terazosin.Approved, Investigational
ArotinololArotinolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Terazosin.Approved, Investigational
AtenololAtenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
AvanafilAvanafil may increase the hypotensive activities of Terazosin.Approved
AzelnidipineTerazosin may increase the hypotensive activities of Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Terazosin is combined with Azilsartan medoxomil.Approved
AzimilideTerazosin may increase the hypotensive activities of Azimilide.Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Terazosin.Experimental
BarbitalBarbital may increase the hypotensive activities of Terazosin.Illicit
BarnidipineTerazosin may increase the hypotensive activities of Barnidipine.Approved
BefunololBefunolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Terazosin.Approved, Investigational
BencyclaneTerazosin may increase the hypotensive activities of Bencyclane.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Terazosin.Approved
BenidipineTerazosin may increase the hypotensive activities of Benidipine.Approved, Investigational
BepridilTerazosin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetaxololBetaxolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BevantololBevantolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BisoprololBisoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BitolterolTerazosin may decrease the vasoconstricting activities of Bitolterol.Withdrawn
BopindololBopindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Terazosin.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Terazosin.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Terazosin.Approved
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Terazosin.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Terazosin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Terazosin.Approved, Investigational
BucindololBucindolol may increase the orthostatic hypotensive activities of Terazosin.Investigational
BufuralolBufuralol may increase the orthostatic hypotensive activities of Terazosin.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin.Approved
BunazosinTerazosin may increase the antihypertensive activities of Bunazosin.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Terazosin.Approved, Investigational
BupranololBupranolol may increase the orthostatic hypotensive activities of Terazosin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Terazosin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Captopril.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Terazosin.Approved
CarboxyamidotriazoleTerazosin may increase the hypotensive activities of Carboxyamidotriazole.Investigational
CaroverineTerazosin may increase the hypotensive activities of Caroverine.Experimental
CarteololCarteolol may increase the orthostatic hypotensive activities of Terazosin.Approved
CarvedilolCarvedilol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
CeliprololCeliprolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Terazosin.Approved, Vet Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Terazosin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Terazosin is combined with Cilazapril.Approved
CilnidipineTerazosin may increase the hypotensive activities of Cilnidipine.Approved, Investigational
CinnarizineTerazosin may increase the hypotensive activities of Cinnarizine.Approved, Investigational
CirazolineTerazosin may decrease the vasoconstricting activities of Cirazoline.Experimental
ClenbuterolTerazosin may decrease the vasoconstricting activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Terazosin is combined with Clevidipine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Terazosin.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Terazosin.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Terazosin.Approved
CloranololCloranolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Terazosin.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Terazosin.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Terazosin.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Terazosin.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Terazosin.Investigational
DarodipineTerazosin may increase the hypotensive activities of Darodipine.Experimental
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Terazosin.Approved
DetomidineTerazosin may decrease the vasoconstricting activities of Detomidine.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Terazosin.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Terazosin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Terazosin is combined with Dinutuximab.Approved
DipivefrinTerazosin may decrease the vasoconstricting activities of Dipivefrin.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Terazosin.Approved
DobutamineTerazosin may decrease the vasoconstricting activities of Dobutamine.Approved
DopexamineTerazosin may decrease the vasoconstricting activities of Dopexamine.Investigational
DotarizineTerazosin may increase the hypotensive activities of Dotarizine.Investigational
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Terazosin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Terazosin.Approved, Investigational
DroxidopaTerazosin may decrease the vasoconstricting activities of Droxidopa.Approved, Investigational
DuloxetineTerazosin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Terazosin.Approved
EfonidipineTerazosin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Terazosin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin.Approved
EpanololEpanolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
EperisoneTerazosin may increase the hypotensive activities of Eperisone.Approved, Investigational
EphedrineTerazosin may decrease the vasoconstricting activities of Ephedrine.Approved
EpinastineTerazosin may decrease the vasoconstricting activities of Epinastine.Approved, Investigational
EpinephrineTerazosin may decrease the vasoconstricting activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Terazosin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Terazosin.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Terazosin.Approved
ErgotamineTerazosin may decrease the vasoconstricting activities of Ergotamine.Approved
EsmololEsmolol may increase the orthostatic hypotensive activities of Terazosin.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.Approved
EtilefrineTerazosin may decrease the vasoconstricting activities of Etilefrine.Withdrawn
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Terazosin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.Approved, Investigational
FendilineTerazosin may increase the hypotensive activities of Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Terazosin.Approved
FenoterolTerazosin may decrease the vasoconstricting activities of Fenoterol.Approved, Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Terazosin.Approved, Investigational
FlunarizineTerazosin may increase the hypotensive activities of Flunarizine.Approved
FormoterolTerazosin may decrease the vasoconstricting activities of Formoterol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Terazosin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Terazosin.Approved, Vet Approved
GabapentinTerazosin may increase the hypotensive activities of Gabapentin.Approved, Investigational
GallopamilTerazosin may increase the hypotensive activities of Gallopamil.Investigational
GuanabenzTerazosin may decrease the vasoconstricting activities of Guanabenz.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Terazosin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Terazosin.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Terazosin.Approved
HexoprenalineTerazosin may decrease the vasoconstricting activities of Hexoprenaline.Approved, Withdrawn
HigenamineTerazosin may decrease the vasoconstricting activities of Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Terazosin.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Terazosin.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Terazosin.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Terazosin.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Terazosin.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Terazosin.Approved
IndenololIndenolol may increase the orthostatic hypotensive activities of Terazosin.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Terazosin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Terazosin.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Terazosin.Approved
IsoetarineTerazosin may decrease the vasoconstricting activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Terazosin.Approved, Vet Approved
IsoprenalineTerazosin may decrease the vasoconstricting activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Terazosin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Terazosin is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Terazosin.Approved
LabetalolLabetalol may increase the orthostatic hypotensive activities of Terazosin.Approved
LacidipineTerazosin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineTerazosin may increase the hypotensive activities of Lamotrigine.Approved, Investigational
LandiololLandiolol may increase the orthostatic hypotensive activities of Terazosin.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Terazosin.Approved
LercanidipineTerazosin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Terazosin is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Terazosin.Approved, Investigational
LevodopaTerazosin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Terazosin.Approved, Investigational
LidoflazineTerazosin may increase the hypotensive activities of Lidoflazine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Terazosin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Terazosin.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Terazosin.Approved
Magnesium SulfateTerazosin may increase the hypotensive activities of Magnesium Sulfate.Approved, Vet Approved
ManidipineTerazosin may increase the hypotensive activities of Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Terazosin.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin.Approved
MedetomidineTerazosin may decrease the vasoconstricting activities of Medetomidine.Vet Approved
MephentermineTerazosin may decrease the vasoconstricting activities of Mephentermine.Approved
MepindololMepindolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
MetaraminolTerazosin may decrease the vasoconstricting activities of Metaraminol.Approved, Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Terazosin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Terazosin.Approved
MethoxamineTerazosin may decrease the vasoconstricting activities of Methoxamine.Approved, Investigational
MethoxyphenamineTerazosin may decrease the vasoconstricting activities of Methoxyphenamine.Experimental
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Terazosin.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Terazosin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Terazosin is combined with Metipranolol.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Terazosin.Approved
MetoprololMetoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
MibefradilTerazosin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrineTerazosin may decrease the vasoconstricting activities of Midodrine.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Terazosin.Approved
MirabegronTerazosin may decrease the vasoconstricting activities of Mirabegron.Approved
MirodenafilMirodenafil may increase the hypotensive activities of Terazosin.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Terazosin.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Terazosin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Terazosin.Approved, Investigational
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Terazosin.Approved, Investigational
NadololNadolol may increase the orthostatic hypotensive activities of Terazosin.Approved
NaftopidilTerazosin may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Terazosin.Approved
NaphazolineTerazosin may decrease the vasoconstricting activities of Naphazoline.Approved
NebivololNebivolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Terazosin is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Terazosin.Approved
NicorandilNicorandil may increase the hypotensive activities of Terazosin.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Terazosin.Approved
NiguldipineTerazosin may increase the hypotensive activities of Niguldipine.Experimental
NiludipineTerazosin may increase the hypotensive activities of Niludipine.Experimental
NilvadipineTerazosin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideTerazosin may increase the hypotensive activities of Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Terazosin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Terazosin.Approved
NitrendipineTerazosin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Terazosin.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Terazosin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Terazosin.Approved
NorepinephrineTerazosin may decrease the vasoconstricting activities of Norepinephrine.Approved
NorfenefrineTerazosin may decrease the vasoconstricting activities of Norfenefrine.Experimental
NylidrinTerazosin may decrease the vasoconstricting activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Terazosin.Approved
OctopamineTerazosin may decrease the vasoconstricting activities of Octopamine.Experimental
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin.Approved, Investigational
OlodaterolTerazosin may decrease the vasoconstricting activities of Olodaterol.Approved
OrciprenalineTerazosin may decrease the vasoconstricting activities of Orciprenaline.Approved
OtiloniumTerazosin may increase the hypotensive activities of Otilonium.Experimental, Investigational
OxprenololOxprenolol may increase the orthostatic hypotensive activities of Terazosin.Approved
OxyfedrineTerazosin may decrease the vasoconstricting activities of Oxyfedrine.Experimental
OxymetazolineTerazosin may decrease the vasoconstricting activities of Oxymetazoline.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Terazosin.Approved, Vet Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Terazosin.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Terazosin.Approved
PenbutololPenbutolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
PentobarbitalPentobarbital may increase the hypotensive activities of Terazosin.Approved, Vet Approved
PerhexilineTerazosin may increase the hypotensive activities of Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Terazosin.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Terazosin.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Terazosin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Terazosin.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Terazosin.Approved
PhenylephrineTerazosin may decrease the vasoconstricting activities of Phenylephrine.Approved
PhenylpropanolamineTerazosin may decrease the vasoconstricting activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PinaveriumTerazosin may increase the hypotensive activities of Pinaverium.Approved
PindololPindolol may increase the orthostatic hypotensive activities of Terazosin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Terazosin.Approved, Investigational
PirbuterolTerazosin may decrease the vasoconstricting activities of Pirbuterol.Approved
Platelet Activating FactorPlatelet Activating Factor may increase the orthostatic hypotensive activities of Terazosin.Experimental
PractololPractolol may increase the orthostatic hypotensive activities of Terazosin.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Terazosin.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Terazosin.Approved
PregabalinTerazosin may increase the hypotensive activities of Pregabalin.Approved, Illicit, Investigational
PrenalterolTerazosin may decrease the vasoconstricting activities of Prenalterol.Experimental
PrenylamineTerazosin may increase the hypotensive activities of Prenylamine.Withdrawn
PrimidonePrimidone may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ProcaterolTerazosin may decrease the vasoconstricting activities of Procaterol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Terazosin.Approved, Investigational, Vet Approved
PropranololPropranolol may increase the orthostatic hypotensive activities of Terazosin.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Terazosin.Approved
PseudoephedrineTerazosin may decrease the vasoconstricting activities of Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Terazosin is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Terazosin.Approved, Investigational
RacepinephrineTerazosin may decrease the vasoconstricting activities of Racepinephrine.Approved
RactopamineTerazosin may decrease the vasoconstricting activities of Ractopamine.Vet Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Terazosin.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Terazosin.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Terazosin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Terazosin.Approved
ReproterolTerazosin may decrease the vasoconstricting activities of Reproterol.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Terazosin.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Terazosin.Approved, Investigational
RilmenidineTerazosin may decrease the vasoconstricting activities of Rilmenidine.Investigational
RimiterolTerazosin may decrease the vasoconstricting activities of Rimiterol.Experimental
RiociguatThe risk or severity of adverse effects can be increased when Terazosin is combined with Riociguat.Approved
RisedronateTerazosin may increase the hypotensive activities of Risedronate.Approved, Investigational
RisperidoneTerazosin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitobegronTerazosin may decrease the vasoconstricting activities of Ritobegron.Investigational
RitodrineTerazosin may decrease the vasoconstricting activities of Ritodrine.Approved, Investigational
RomifidineTerazosin may decrease the vasoconstricting activities of Romifidine.Vet Approved
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Terazosin.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Terazosin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Terazosin.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Terazosin.Approved
SalbutamolTerazosin may decrease the vasoconstricting activities of Salbutamol.Approved, Vet Approved
SalmeterolTerazosin may decrease the vasoconstricting activities of Salmeterol.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Terazosin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Terazosin.Approved, Investigational, Vet Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Terazosin.Approved, Vet Approved
SildenafilSildenafil may increase the hypotensive activities of Terazosin.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Terazosin.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Terazosin.Approved
SolabegronTerazosin may decrease the vasoconstricting activities of Solabegron.Investigational
SotalolSotalol may increase the orthostatic hypotensive activities of Terazosin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Terazosin.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Terazosin.Approved, Investigational
SynephrineTerazosin may decrease the vasoconstricting activities of Synephrine.Experimental
TadalafilTadalafil may increase the hypotensive activities of Terazosin.Approved, Investigational
TalinololTalinolol may increase the orthostatic hypotensive activities of Terazosin.Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Terazosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Terazosin.Approved, Investigational
TerbutalineTerazosin may decrease the vasoconstricting activities of Terbutaline.Approved
TerodilineTerazosin may increase the hypotensive activities of Terodiline.Experimental
TertatololTertatolol may increase the orthostatic hypotensive activities of Terazosin.Experimental
TetrahydropalmatineTerazosin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Terazosin.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Terazosin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Terazosin.Approved, Withdrawn
TimololTimolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Terazosin.Approved
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Terazosin.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Terazosin.Approved, Withdrawn
Tolfenamic AcidTerazosin may increase the hypotensive activities of Tolfenamic Acid.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Terazosin.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Terazosin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Terazosin.Approved
TranilastTerazosin may increase the hypotensive activities of Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terazosin.Approved
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Terazosin.Approved, Investigational, Nutraceutical
TretoquinolTerazosin may decrease the vasoconstricting activities of Tretoquinol.Experimental
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin.Approved
TrimazosinTerazosin may increase the antihypertensive activities of Trimazosin.Experimental
TulobuterolTerazosin may decrease the vasoconstricting activities of Tulobuterol.Investigational
UdenafilUdenafil may increase the hypotensive activities of Terazosin.Approved, Investigational
UrapidilTerazosin may increase the antihypertensive activities of Urapidil.Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Terazosin.Approved, Investigational
VardenafilVardenafil may increase the hypotensive activities of Terazosin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Terazosin.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Terazosin.Approved, Investigational
VinpocetineTerazosin may increase the hypotensive activities of Vinpocetine.Investigational
XamoterolTerazosin may decrease the vasoconstricting activities of Xamoterol.Experimental
XylazineTerazosin may decrease the vasoconstricting activities of Xylazine.Vet Approved
XylometazolineTerazosin may increase the hypotensive activities of Xylometazoline.Approved
YM-178Terazosin may decrease the vasoconstricting activities of YM-178.Investigational
ZiconotideTerazosin may increase the hypotensive activities of Ziconotide.Approved
Food Interactions
Not Available

References

Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, "Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines." U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301]
External Links
Human Metabolome Database
HMDB15293
KEGG Drug
D08569
KEGG Compound
C07127
PubChem Compound
5401
PubChem Substance
46509129
ChemSpider
5208
BindingDB
50033111
ChEBI
9445
ChEMBL
CHEMBL611
Therapeutic Targets Database
DAP000371
PharmGKB
PA451612
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Terazosin
ATC Codes
G04CA03 — Terazosin
AHFS Codes
  • 24:20.00 — Alpha-adrenergic Blocking Agents
FDA label
Download (1020 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2Not Yet RecruitingPreventionCarotid Artery Stenosis1
2, 3CompletedTreatmentDisorder of Urinary Stent1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
4CompletedPreventionNonvalvular Atrial Fibrillation1
4CompletedTreatmentHyperhidrosis1
4CompletedTreatmentProstatic Hyperplasia1
4WithdrawnTreatmentBenign Prostatic Hyperplasia (BPH)1
Not AvailableCompletedTreatmentAntidepressant Induced Excessive Sweating1
Not AvailableCompletedTreatmentHypertensive / Lower Urinary Tract Symptoms (LUTS)1
Not AvailableRecruitingPreventionCardiovascular Effects1
Not AvailableTerminatedTreatmentProstatic Hyperplasia / Urinary Retention1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
TabletOral10 mg
Kit; tabletOral
CapsuleOral1 mg/1
CapsuleOral10 mg/1
CapsuleOral2 mg/1
CapsuleOral5 mg/1
TabletOral1 mg
TabletOral2 mg
TabletOral5 mg
Prices
Unit descriptionCostUnit
Hytrin 10 mg Tablet1.85USD tablet
Terazosin HCl 1 mg capsule1.67USD capsule
Terazosin HCl 10 mg capsule1.67USD capsule
Terazosin HCl 2 mg capsule1.67USD capsule
Terazosin HCl 5 mg capsule1.67USD capsule
Hytrin 5 mg Tablet1.26USD tablet
Hytrin 2 mg Tablet0.93USD tablet
Apo-Terazosin 10 mg Tablet0.92USD tablet
Novo-Terazosin 10 mg Tablet0.92USD tablet
Nu-Terazosin 10 mg Tablet0.92USD tablet
Pms-Terazosin 10 mg Tablet0.92USD tablet
Ratio-Terazosin 10 mg Tablet0.92USD tablet
Hytrin 1 mg Tablet0.73USD tablet
Apo-Terazosin 5 mg Tablet0.63USD tablet
Novo-Terazosin 5 mg Tablet0.63USD tablet
Nu-Terazosin 5 mg Tablet0.63USD tablet
Pms-Terazosin 5 mg Tablet0.63USD tablet
Ratio-Terazosin 5 mg Tablet0.63USD tablet
Apo-Terazosin 2 mg Tablet0.46USD tablet
Novo-Terazosin 2 mg Tablet0.46USD tablet
Nu-Terazosin 2 mg Tablet0.46USD tablet
Pms-Terazosin 2 mg Tablet0.46USD tablet
Ratio-Terazosin 2 mg Tablet0.46USD tablet
Apo-Terazosin 1 mg Tablet0.37USD tablet
Novo-Terazosin 1 mg Tablet0.37USD tablet
Nu-Terazosin 1 mg Tablet0.37USD tablet
Pms-Terazosin 1 mg Tablet0.37USD tablet
Ratio-Terazosin 1 mg Tablet0.37USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5294615No1993-04-292013-04-29Us
US5212176No1993-06-292010-06-29Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)273 °CPhysProp
water solubility29.7mg/mLNot Available
logP1Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.5 mg/mLALOGPS
logP1.12ALOGPS
logP1.18ChemAxon
logS-2.4ALOGPS
pKa (Strongest Acidic)19.93ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area103.04 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability41.26 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9646
Caco-2 permeable+0.8868
P-glycoprotein substrateSubstrate0.698
P-glycoprotein inhibitor INon-inhibitor0.5666
P-glycoprotein inhibitor IINon-inhibitor0.8619
Renal organic cation transporterNon-inhibitor0.6319
CYP450 2C9 substrateNon-substrate0.8864
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateSubstrate0.7753
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9435
CYP450 2D6 inhibitorNon-inhibitor0.9628
CYP450 2C19 inhibitorNon-inhibitor0.9492
CYP450 3A4 inhibitorNon-inhibitor0.7905
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.901
Ames testNon AMES toxic0.5943
CarcinogenicityNon-carcinogens0.906
BiodegradationNot ready biodegradable0.9785
Rat acute toxicity2.2262 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8368
hERG inhibition (predictor II)Inhibitor0.8204
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0049000000-86650e3e374df663aa35
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0059000000-ca9adf5daab9e5e9b6e7
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000e-1292000000-9081c5bb64e8d096db78

Taxonomy

Description
This compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
N-arylpiperazines
Alternative Parents
Quinazolinamines / Anisoles / Dialkylarylamines / Alkyl aryl ethers / Aminopyrimidines and derivatives / Imidolactams / Tetrahydrofurans / Tertiary carboxylic acid amides / Heteroaromatic compounds / Amino acids and derivatives
show 8 more
Substituents
N-arylpiperazine / Quinazolinamine / Diazanaphthalene / Quinazoline / Anisole / Dialkylarylamine / Alkyl aryl ether / Aminopyrimidine / Pyrimidine / Imidolactam
show 22 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
primary amino compound, furans, quinazolines, piperazines (CHEBI:9445)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1A
Uniprot ID
P35348
Uniprot Name
Alpha-1A adrenergic receptor
Molecular Weight
51486.005 Da
References
  1. Chapple CR: Medical therapy and quality of life. Eur Urol. 1998;34 Suppl 2:10-7; discussion 46. [PubMed:9732824]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Lee E, Lee C: Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. Br J Urol. 1997 Oct;80(4):606-11. [PubMed:9352700]
  4. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427]
  5. Na YJ, Guo YL, Gu FL: Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group. J Med. 1998;29(5-6):289-304. [PubMed:10503165]
  6. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name
ADRA1B
Uniprot ID
P35368
Uniprot Name
Alpha-1B adrenergic receptor
Molecular Weight
56835.375 Da
References
  1. Boyle P, Robertson C, Manski R, Padley RJ, Roehrborn CG: Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology. 2001 Nov;58(5):717-22. [PubMed:11711348]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  3. Simpson P: Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ Res. 1985 Jun;56(6):884-94. [PubMed:2988814]
  4. Vincent J, Dachman W, Blaschke TF, Hoffman BB: Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans. J Clin Invest. 1992 Nov;90(5):1763-8. [PubMed:1358918]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Alpha1-adrenergic receptor activity
Specific Function
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name
ADRA1D
Uniprot ID
P25100
Uniprot Name
Alpha-1D adrenergic receptor
Molecular Weight
60462.205 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the ...
Gene Name
KCNH2
Uniprot ID
Q12809
Uniprot Name
Potassium voltage-gated channel subfamily H member 2
Molecular Weight
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH6
Uniprot ID
Q9H252
Uniprot Name
Potassium voltage-gated channel subfamily H member 6
Molecular Weight
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Voltage-gated potassium channel activity
Specific Function
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name
KCNH7
Uniprot ID
Q9NS40
Uniprot Name
Potassium voltage-gated channel subfamily H member 7
Molecular Weight
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783]

Drug created on June 13, 2005 07:24 / Updated on November 22, 2017 12:41